Silvercrest Asset Management Group LLC Gilead Sciences, Inc. Transaction History

Silvercrest Asset Management Group LLC

$13.6 Billion
Q1 2025

A detailed history of Silvercrest Asset Management Group LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 21,040 shares of GILD stock, worth $2.32 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

21,040

Previous 17,023 23.6%

Holding current value

$2.32 Million

Previous $1.57 Million 49.94%

% of portfolio

0.02%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$89.14 - $117.41 $358,075 - $471,635	4,017 Added 23.6%	21,040 $2.36 Million
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $1.08 Million - $1.24 Million	-17,023 Reduced 50.0%	17,023 $1.17 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $1.08 Million - $1.24 Million	17,023 Added 100.0%	34,046 $2.34 Million
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $1,932 - $2,356	-27 Reduced 0.16%	17,023 $1.25 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $37,807 - $42,874	516 Added 3.12%	17,050 $1.38 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $7,394 - $8,067	-100 Reduced 0.6%	16,534 $1.24 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $17,102 - $19,507	225 Added 1.37%	16,634 $1.28 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $5,411 - $6,165	-70 Reduced 0.42%	16,409 $1.36 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $4,549 - $6,531	73 Added 0.44%	16,479 $1.41 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $10,121 - $11,561	-170 Reduced 1.03%	16,406 $1.01 Million
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $11,544 - $13,002	-200 Reduced 1.19%	16,576 $1.03 Million
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $59,541 - $74,612	-1,028 Reduced 5.77%	16,776 $997,000
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $40,355 - $45,804	-622 Reduced 3.38%	17,804 $1.29 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $5,009 - $5,404	-74 Reduced 0.4%	18,426 $1.29 Million
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $15,867 - $17,337	-250 Reduced 1.33%	18,500 $1.27 Million
Q1 2021 May 17, 2021	SELL	$60.0 - $68.46 $273,060 - $311,561	-4,551 Reduced 19.53%	18,750 $1.21 Million
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $73,305 - $83,527	-1,294 Reduced 5.26%	23,301 $1.36 Million
Q3 2020 Nov 16, 2020	SELL	$62.1 - $78.08 $90,790 - $114,152	-1,462 Reduced 5.61%	24,595 $1.55 Million
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $31,829 - $36,960	-440 Reduced 1.66%	26,057 $2.01 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $323,421 - $414,256	-5,164 Reduced 16.31%	26,497 $1.98 Million
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $77,025 - $84,725	1,250 Added 4.11%	31,661 $2.06 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $137,522 - $151,800	-2,200 Reduced 6.75%	30,411 $1.93 Million
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $314,299 - $352,450	-5,080 Reduced 13.48%	32,611 $2.2 Million
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $139,879 - $156,701	-2,237 Reduced 5.6%	37,691 $2.45 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $13,318 - $17,380	-220 Reduced 0.55%	39,928 $2.5 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $115,687 - $128,087	-1,623 Reduced 3.89%	40,148 $3.1 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $564,780 - $658,794	-8,705 Reduced 17.25%	41,771 $2.96 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $251,662 - $306,804	3,455 Added 7.35%	50,476 $3.81 Million
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $179,013 - $210,136	2,516 Added 5.65%	47,021 $3.37 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $3.21 Million - $3.8 Million	44,505	44,505 $3.61 Million

Others Institutions Holding GILD

# of Institutions

2,288

Shares Held

997M

Call Options Held

9.62M

Put Options Held

10M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $138B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.

Account

Silvercrest Asset Management Group LLC Gilead Sciences, Inc. Transaction History